Rada Savic 1 Alain Munafo 2, Mats Karlsson 1

Similar documents
A Semi-mechanistic Model of Lymphocyte Dynamics in Patients with Multiple Sclerosis Treated with Cladribine Tablets

CLADRIBINE TABLETS DOSING RULES

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis

News Release. March 29, 2019

European Commission Grants Approval for Mavenclad (Cladribine Tablets)

Modeling disease progression in acute stroke by simultaneously using the NIH Stroke Scale, Scandinavian Stroke Scale and the Barthel Index

Data on Investigational Cladribine Tablets and Rebif (interferon beta-1a) in Relapsing Forms of Multiple Sclerosis (MS) to be Presented at EAN 2018

Cost-effectiveness of cladribine (Mavenclad ) for the

Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493

Application of Item Response Theory to ADAS-cog Scores Modeling in Alzheimer s Disease

Clinician s view of Benefit-Risk

Prescriber s Guide IMPORTANT INFORMATION ON MINIMISING THE RISK OF ADVERSE EVENTS

AN ATYPICAL JOINT MODEL OF PSA AND CTC COUNT KINETICS DURING TREATMENT IN PROSTATE CANCER

A model-based analysis to describe bedaquiline s exposure-response relationship and predict the impact of drugdrug interactions

Hoa Van Le, MD, PhD (Presenter) PAREXEL International ISPOR 22nd Annual International Meeting, Boston, MA. May 23, 2017

Sample-size re-estimation in Multiple Sclerosis trials

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Treating MS patients earlier in the disease progression may affect long-term outcomes 1-4

14 abstracts to be presented, further characterizing the complementary profiles of Mavenclad (cladribine tablets) and Rebif (interferon beta-1a)

Changing EDSS progression in placebo cohorts in relapsing MS:

Synopsis (C1034T02) CNTO 95 Module 5.3 Clinical Study Report C1034T02

Case Study in Placebo Modeling and Its Effect on Drug Development

Population pharmacokinetic pharmacodynamic analysis for sugammadex-mediated. reversal of rocuronium-induced. neuromuscular blockade

Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets

Hot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing remitting multiple sclerosis: the CLARITY Extension study

EAN Amsterdam June 23-27, 2017

WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example

RTTE modelling of opioid consumption in postoperative pain

Media Release. Basel, 10 November 2017

João A. Abrantes 1, Alexander Solms 2, Dirk Garmann 3, Elisabet I. Nielsen 1, Siv Jönsson 1, Mats O. Karlsson 1

Understandable Statistics

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

2013 MS Phenotype Descriptions: Relapsing MS 1

Population Pharmacokinetics and Pharmacodynamics as a Tool in Drug Development. Leon Aarons Manchester Pharmacy School University of Manchester

Statistical Models for Censored Point Processes with Cure Rates

Annex IV Scientific conclusions

Statistical Methods for the Evaluation of Treatment Effectiveness in the Presence of Competing Risks

Fingolimod for the treatment of Relapsing-Remitting Multiple Sclerosis

Benefit/Risk Strategies in Selecting Therapeutic Solutions for MS: HCP and Patient Viewpoints

Time to Lowest BIS after an Intravenous Bolus and an Adaptation of the Time-topeak-effect

Positive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine

A NOVEL PHARMACODYNAMIC MODEL FOR TREATMENT OF TUBERCULOSIS USING DAYS TO POSITIVITY IN AUTOMATED LIQUID MYCOBACTERIAL CULTURE

MEDIA BACKGROUNDER. Teriflunomide: A novel oral drug being investigated for the treatment of Multiple Sclerosis (MS)

Modeling & Simulation to support evaluation of Safety and Efficacy of Drugs in Older Patients

Kaspar Rufibach Methods, Collaboration, and Outreach Group (MCO) Department of Biostatistics, Roche Basel

PEDIATRIC MULTIPLE SCLEROSIS CLINICAL AND TRANSCRIPTIONAL ASPECTS M U L T I P L E S C L E R O S I S C E N T E R

Current Enrolling Clinical Trials

Media Release. Basel 12 January 2018

Effective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development. Pantelis Vlachos.

Exposure-response in the presence of confounding

MEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease

Title: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations

Graphical display of population data

The Time Course of Placebo Response in Clinical Trials

Bayesian Joint Modelling of Benefit and Risk in Drug Development

Tutorial: Introduction to Markov modelling

Clinical Pharmacology. Pharmacodynamics the next step. Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Clinical Study Synopsis for Public Disclosure

ASSESSING LONG-TERM BENEFITS OF IMMUNOTHERAPY BASED ON EARLY TUMOR ASSESSMENT DATA

Model based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking

A FRAMEWORK FOR SIMULATIONS IN CLINICAL RESEARCH

Poisson regression. Dae-Jin Lee Basque Center for Applied Mathematics.

Evidence from bone marrow transplantation

Supplementary Online Content

Varun Goel 1, Nathalie H Gosselin 2, Claudia Jomphe 2, Husain Attarwala 1, Xiaoping (Amy) Zhang 1, JF Marier 2, Gabriel Robbie 1

Giancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group. Assessment of oral laquinimod in preventing progression of Multiple Sclerosis

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION

TRANSPARENCY COMMITTEE Opinion 05 March 2014

Submissions to be lodged by 4 October at:

PKPD modelling to optimize dose-escalation trials in Oncology

Biomath M263 Clinical Pharmacology

SYNOPSIS. The study results and synopsis are supplied for informational purposes only.

PAGE Meeting 2003 Verona, Italy

TB ReFLECT Meta-Analysis of Fluoroquinolone-Containing Regimens for the Treatment of Drug-Susceptible TB

MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014

PKPD-Modelling of QT Prolongation Following Deliberate Self-Poisonings with Citalopram

Indications and labelling; general aspects. EMA-Payer Community meeting Sept 19th, 2017 Kristina Dunder, CHMP member

Disease Progress. Clinical Pharmacology = Disease Progress + Drug Action. Outline. Parkinson s Disease. Interpretation of ELLDOPA

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI

BASIC PHARMACOKINETICS

Cost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD)

Everolimus for the Treatment of Advanced Renal Cell Carcinoma (arcc ) - Additional Analysis Using RPSFT

Progress in the field

Overview. Fundamentals of functional MRI. Task related versus resting state functional imaging for sensorimotor mapping

Statistical Models for Bias and Overdiagnosis in Prostate Cancer Screening

Data Analysis Using Regression and Multilevel/Hierarchical Models

SOME STATISTICAL CONSIDERATIONS IN THE DESIGN AND ANALYSIS OF EQUIVALENCE STUDIES USING PHARMACODYNAMIC AND CLINICAL ENDPOINTS

Clinical Applications for Change-Point Analysis of Herpes Zoster Pain

Investor Update. Basel, 23 April 2018

Utilizing the items from the MDS-UPDRS score to increase drug effect detection power in de novo idiopathic Parkinson's disease patients

Investor Update. Downloads. Services PDF. Basel, 17 July 2017

MS Academia: Multiple sclerosis advanced course

Statistical Science Issues in HIV Vaccine Trials: Part I

BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018

Pharmacometric Modelling to Support Extrapolation in Regulatory Submissions

The Effects of Daclizumab High Yield Process (DAC HYP) on Patient Centered Functional Outcomes: Results From the DECIDE Study

Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis

Transcription:

Population Pharmacodynamics of Cladribine Tablets Therapy in Patients with Multiple Sclerosis: Relationship between Magnetic Resonance Imaging and Clinical Outcomes Rada Savic 1 Alain Munafo 2, Mats Karlsson 1 (1) Dept of Pharmaceutical Biosciences, Uppsala University, Sweden (2) Modeling and Simulation, Merck Serono S.A. Geneva, Switzerland* *An affiliate of Merck KGaA, Darmstadt, Germany

Background Relapsing forms of multiple sclerosis (MS) are characterized by: Unpredictable periods of remission Slow disease progression Substantial inter-patient variability Poorly-understood relationship with biomarkers (MRI) Making it a challenge to quantify effects of therapies on disease progression dynamics MRI, magnetic resonance imaging 2

Aim We previously developed NLME models to characterize the effect of cladribine tablets on clinical outcomes in patients with relapsing remitting multiple sclerosis 1 2 These models allow predictions of relapse rate dynamics and disability progression based on an individual s disease activity, baseline characteristics, renal clearance and cladribine dose AIM To integrate key MRI readouts into models relating cladribine exposure to clinical efficacy, and delineate the poorly-understood relationship between MRI and clinical markers of MS progression NLME, nonlinear mixed-effects 3 1. Savic R et al. ECTRIMS 2010 (Poster P477); 2. Savic R et al. ACoP 2011 (Poster M-9-5)

Data, clinical endpoints, biomarkers Data (i) CLARITY trial (96 weeks) 1,326 patients with relapsing remitting MS 3 arms (placebo or cladribine tablets at cumulative doses of 3.5 and 5.25 mg/kg over 96 weeks, given as 4 and 6 short 4 5-day courses) (ii) OWIMS trial (48 weeks) and PRISMS trial (96 weeks) Additional 287 placebo patients with relapsing remitting MS Clinical endpoints Expanded Disability Status Scale (EDSS) score Categorical variable (0 10 scale, with 0.5-point increments) Relapse rate Repeated time-to-event variable (up to 6 relapses, over 96 weeks) MRI Biomarkers I. T2 lesion volume burden of disease (BOD) (continuous variable) II. Combined unique (CU) lesion count (count variable) 4

Modeling strategy (i) Develop population models for time course of biomarkers (with covariates) CU model BOD model (ii) Link the time course of biomarkers with the time course of clinical endpoints Final aim: establish predictive models for 2 major clinical endpoints: 1) Exposure MRI BOD EDSS 2) Exposure MRI CU lesions relapse rate (RR) 5

STEP I: MODEL DEVELOPMENT FOR BIOMARKERS

Raw data Large variability, skewed baseline Large variability in placebo group, variability decreased with cladribine Observed BOD cm 3 100,000 Observed CU lesion count 50,000 0 30 10 Observed data, BOD, CLARITY Placebo 3.5 mg/kg 5.25 mg/kg 0 200 400 600 800 0 200 400 600 800 0 200 400 600 800 Time (days) Observed data, CU lesions, CLARITY Placebo 3.5 mg/kg 5.25 mg/kg 7 200 400 600 200 400 600 200 400 600 Time (days)

Modeling strategy Development of the placebo model Constant vs time changes CU lesions: choice of count data model (overdispersion) Count model Data # of parameters Parameters OFV Poisson Placebo 2 λ, IIV (λ) 9209 Zero inflated Placebo 4 λ, IIV (λ) p, IIV (p) Generalized Poisson Placebo 4 λ, IIV (λ) δ, IIV (δ) Inverse binomial Placebo 4 λ, IIV (λ) OVDP, IIV (OVDP) 8327 8479 7732 Development of the drug model OVDP, overdispersion factor 8

General MRI model CdA 1-Eff k in MRI lesions k out Eff = Exps = E max x Exps Exps 50 + Exps CD x CL CR_median CL CR CD Exps k in k out CL CR CL CR_median Eff Exps 50 = cumulative dose = exposure = production rate constant = elimination rate constant = creatinine clearance = median creatinine clearance = drug effect = exposure needed for half maximal effect 9 CdA, cladribine

Covariate model for biomarkers BOD 1. Baseline EDSS, MSD and age on baseline BOD ( OFV=95, 35 and 26) BOD increases with greater baseline EDSS and duration of disease, and decreases with greater age 2. Age on Emax ( OFV=22) Emax decreases with greater age CU lesions 1. AGE on mean count ( OFV=110) 2. SEX on EC50 ( OFV=8): lower EC50 in men 10 BOD 0 = θ 1 (1 + 0.185 (BASE 2.5)) (1 + 0.0364 (MSD 6.22)) (1 0.15 (Age 38)) Emax= θ 2 (1 0.027 (Age 38)) λ = θ 1 (1 0.0348 (Age 38)) MSD, duration of disease

Diagnostics: visual predictive check (BOD) Placebo 3.5 mg/kg 5.25 mg/kg BOD, cm 3 60,000 40,000 20,000 0 200 400 600 800 0 200 400 600 800 0 200 400 600 800 Time (days) 11

STEP II: BIOMARKER CLINICAL ENDPOINTS MODELS

Clinical endpoint I: EDSS disease progression model for MS DISEASE PROGRESSION MODEL Linear model where baseline (EDSS 0 ) and disease progression rate (SL) are estimated from the data Strong correlation EDSS 0 ~SL EDSS 0 related to patient age and disease duration EXPOSURE RESPONSE MODEL Dual effect: disease-modifying and symptomatic EDSS t = EDSS 0 + ((1 EffP) x SL x 10 EDSS 0 x TIME) x (1 EffS) 2 x 365 EffS = E max Exps i Exps 50 + Exps i Exps = CumDose x CL CR_median CL CR EDSS score 8 6 4 2 0 EDSS t = EDSS 0 + SL x TIME x 10 EDSS 0 2 x 365 EDSS score 2.75 2.70 2.65 2.60 2.55 2.50 Placebo Disease-modifying only Symptomatic only Both 2 0 200 400 600 800 Time (days) 0 0 0.5 1.0 1.5 2.0 Time (years) 13

Exploratory analysis Observed EDSS vs predicted BOD 8 Placebo 3.5 mg/kg 5.25 mg/kg EDSS score 6 4 2 0 0 20,000 60,000 100,000 0 20,000 60,000 100,000 0 20,000 60,000 100,000 BOD (model prediction) 14

Joint MRI burden of disease EDSS model CdA 1-Eff Eff = AGE E max x Exps Exps 50 + Exps Exps = CD x CL CR_median CL CR k in BOD k out EDSS (x2) Disease progression for a typical patient 5.9 5.7 5.5 5.3 5.1 Eff=EffS+EffP 0.0 0.5 1.0 1.5 2.0 Time (years) EDSS t = EDSS 0 S0MRI + (1 EffP) Direct relationship AGE, MSD SL (10 EDSS 0 ) TIME 2 x 365 (1 EffS) EDSSb, MSD, AGE CD = cumulative dose Exps = exposure k in = production rate constant k out = elimination rate constant CL CR = creatinine clearance CL CR_median = median creatinine clearance Eff = drug effect Exps 50 = exposure needed for half maximal effect LNK = coefficient of BOD EDSS relationship S0MRI = 1 + LNK Ln(BOD ) 9.21 15 CdA, cladribine; MSD, duration of disease

Overview of key models The overview of likelihood comparison for some of the tested models Model -2*log(likelihood) EDSS model, with drug exposure 5961 EDSS model, with BOD 5929 EDSS model, with BOD and drug exposure 5878 16

Disease progression model with BOD and drug effect Cladribine tablets Cladribine tablets Placebo 3.5 mg/kg 5.25 mg/kg 8 EDSS score 6 4 2 0 0 200 400 600 800 0 200 400 600 800 0 200 400 600 800 Time (days)

Clinical endpoint II: relapse rate Baseline hazard (placebo model with covariate effect) HZ t = HZ 0 x COVH x γ x (HZ 0 x t ) γ 1 COVH = 1 + SI x (EXBN EXBN median ) 0.0016 HZ 0 HZ t γ SI EXBN = baseline hazard = instantaneous hazard at time t = shape factor = slope of EXBN HZ t relationship = # relapses in the year prior to study Placebo baseline hazard, HZ 1 0.0012 0.0008 0.0004 3 2 1 0 Baseline disease activity = # relapses one year prior to study 0 0 0.5 1 1.5 2 Time (years) 20

Joint MRI CU lesions relapse rate model CdA E max x Exps_cu Eff_cu = Exps_cu 50 + Exps_cu 1 Eff_cu Exps_cu = CD x CL CR_median CL CR AGE, SEX k in k out CU lesions Model for relapse rate hazard BIOM = 1 + LNK1 x (CU lesion CU lesion_median ) 21 HZ t = HZ 0 xcovh x BIOM x (1 Eff_rr) x γ x (HZ 0 x t) γ 1 E max x Exps Disease activity Eff_rr = Exps_rr 50 + Exps CdA, cladribine CD Exps k in k out CL CR CL CR_median Eff Exps 50 LNK1 HZ 0 HZ t γ = cumulative dose = exposure = production rate constant = elimination rate constant = creatinine clearance = median creatinine clearance = drug effect = exposure needed for half maximal effect = coefficient of CU RR relationship = baseline hazard = instantaneous hazard at time t = shape factor

Overview of key final RR and CU models Model -2*log(likelihood) Final RR model, without CU lesions 7816 Final CU lesion model 7070 Joint CU and RR model with link 14850 <7070+7816=14886 22

Visual predictive check: joint CU and RR model Placebo arm 3.5 mg/kg arm 5.25 mg/kg arm 100 100 100 Relapse #1 90 90 90 80 80 80 70 70 70 Relapse #2 Probability relapse-free (%) 100 95 90 85 200 400 600 200 400 600 200 400 600 100 100 95 95 90 90 85 85 200 400 600 200 400 600 200 400 600 Relapse #3 100 98 100 98 100 98 96 96 96 94 94 94 92 92 92 The blue line represents the observed Kaplan-Meier curve; the orange shaded area displays 90% prediction intervals derived from model simulations. Probability relapse-free is defined as percentage of patients not experiencing 1 (upper), 2 (middle), or 3 (lower) relapses 23 200 400 600 200 400 600 200 400 600 Time (days) Time (days) Time (days)

Conclusions Despite major technical challenges and poor mechanistic understanding about MRI clinical outcome relationships, links between MRI lesion dynamics and clinical endpoints were established The proposed exposure biomarker clinical endpoints models integrate a significant amount of knowledge and data, representing a useful platform for quantitative understanding of the MS time course 25

Disclosures and acknowledgments This study was funded by Merck Serono S.A. Geneva, Switzerland* R Savic and M Karlsson are paid consultants for Merck Serono S.A.* A Munafo is an employee of Merck Serono S.A.* Cladribine tablets treatment is not approved in the USA. Marketing authorization for the use of cladribine tablets in patients with RRMS has been granted in Russia and Australia (2010). Please refer to full prescribing information for further details on use. *An affiliate of Merck KGaA, Darmstadt, Germany 26

BOD predictions w/ and w/o EDSS0 as covariate 27